Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation -: A prospective randomized controlled study

被引:155
作者
Lubetsky, A
Yonath, H
Olchovsky, D
Loebstein, R
Halkin, H
Ezra, D
机构
[1] Chaim Sheba Med Ctr, Dept Med, Anticoagulat Clin, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Div Clin Pharmacol, IL-52621 Tel Hashomer, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
D O I
10.1001/archinte.163.20.2469
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Treatment of patients with excessive anticoagulation is routinely done by intravenous phytonadione (vitamin K-1). Oral administration of phytonadione has been shown to be an effective alternative to the intravenous route, but these methods have never been compared directly. Our objective was to compare efficacy and safety of intravenous vs oral phytonadione treatment in patients with excessive anticoagulation without bleeding. Methods: The study was a prospective randomized controlled trial of consecutive patients presenting with excessive anticoagulation without major bleeding. Patients with a baseline international normalized ratio (INR) of 6 to 10 (n=44,47 episodes) received either intravenous or oral phytonadione (0.5 mg or 2.5 mg, respectively), and patients with an INR greater than 10 (n = 17, 19 episodes) received I mg or 5 mg, respectively. Efficacy and safety end points were sequential INR changes and the proportion of patients achieving therapeutic range (INR, 2-4), overcorrection (INR<2.0), or undercorrection (INR>4.0) INR values. Results: Sixty-six episodes of excessive anticoagulation were studied, In patients with baseline INR 6-10 the response to intravenous phytonadione was more rapid than in the oral group, and the proportion of patients reaching therapeutic range INR at 6 hours (11/24 vs 0/23) and at 12 hours (16/24 vs; 8/23) was significantly higher. However, mean +/-SD INR values were similar for both groups at 24 hours (2.9 +/- 0.8 vs 2.6 +/- 0.8). Patients in the intravenous group tended to be more often (7/24 vs 2/23) overcorrected (INR<2). In patients with baseline INR values greater than 10 efficacy and safety were comparable for both routes of administration. Conclusion: Oral administration of phytonadione had similar efficacy and safety as intravenously administered phytonadione and may be suitable for treatment of patients with excessive anticoagulation.
引用
收藏
页码:2469 / 2473
页数:5
相关论文
共 22 条
[1]  
ANDERSEN P, 1975, ACTA MED SCAND, V198, P269
[2]  
Crowther MA, 1998, THROMB HAEMOSTASIS, V79, P1116
[3]   Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial [J].
Crowther, MA ;
Julian, J ;
McCarty, D ;
Douketis, J ;
Kovacs, M ;
Biagoni, L ;
Schnurr, T ;
McGinnis, J ;
Gent, M ;
Hirsh, J ;
Ginsberg, J .
LANCET, 2000, 356 (9241) :1551-1553
[4]   Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy - A randomized, controlled trial [J].
Crowther, MA ;
Douketis, JD ;
Schnurr, T ;
Steidl, L ;
Mera, V ;
Ultori, C ;
Venco, A ;
Ageno, W .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (04) :251-254
[5]   ANAPHYLACTIC SHOCK AND VITAMIN-K1 [J].
DELARUBIA, J ;
GRAU, E ;
MONTSERRAT, I ;
ZUAZU, I ;
PAYA, A .
ANNALS OF INTERNAL MEDICINE, 1989, 110 (11) :943-943
[6]   Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation.: A prospective, randomized, open study [J].
Fondevila, CG ;
Grosso, SH ;
Santarelli, MT ;
Pinto, MD .
BLOOD COAGULATION & FIBRINOLYSIS, 2001, 12 (01) :9-16
[7]   A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization [J].
Hung, A ;
Singh, S ;
Tait, RC .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (03) :537-539
[8]   Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation [J].
Hylck, EM ;
Chang, YC ;
Skates, SJ ;
Hughes, RA ;
Singer, DE .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (11) :1612-1617
[9]   RISK-FACTORS FAR INTRACRANIAL HEMORRHAGE IN OUTPATIENTS TAKING WARFARIN [J].
HYLEK, EM ;
SINGER, DE .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (11) :897-902
[10]  
Lubetsky A, 2003, THROMB HAEMOSTASIS, V90, P71